← All trials
NCT06385509
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Apr 26, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 110
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tolmar Inc.Lead sponsor
- ICONCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.